Objectives—To examine the distribution of striatal dopaminergic function in humans with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to determine if there is a caudate-putamen gradient as is seen in idiopathic Parkinson’s disease. Methods—We scanned nine humans ex-posed to MPTP with parkinsonism rang-ing from minimal to severe using [18F]fluorodopa (FD) and high resolution PET. The results were compared with those of 10 patients with Parkinson’s disease and six normal subjects. Results—In the MPTP group there was an equal degree of reduction of dopaminergic function in the caudate and putamen. This was diVerent from the greater putaminal than caudate loss in Parkinson’s disease (p<0.001). Conclusions—Parkin...
The meperidine analogue derivative 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces nigro...
Aim: L-3,4-dihydroxy-6-18F-fluorophenylalanine (FDOPA) PET allows quantification of presynaptic dopa...
Parkinson’s disease (PD) is a highly heterogeneous clinical entity. Patients with young-onset PD (YO...
OBJECTIVES: To examine the distribution of striatal dopaminergic function in humans with parkinsonis...
Transient exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndr...
We have investigated regional changes in dopamine metabolism within the basal ganglia with clinical ...
. .Single photon emission computed tomography SPECT and the dopamine DA transporter tracer, 2 beta-c...
Parkinson\u27s disease (PD) patients have remarkably reduced levels of dopaminergic biomarkers in th...
Neurodegenerative parkinsonisms affect mainly cognitive and motor functions and are syndromes of ove...
Parkinson’s disease (PD) is characterized by the loss of dopamine-producing neurons in the nigrostri...
The MPTP-lesioned monkey is considered as the best animal model for Parkinson's disease (PD). It has...
We investigated the relative differences in dopaminergic function through the whole brain in patient...
Parkinson's disease (PD) is characterized by the loss of dopamine-producing neurons in the nigrostri...
Parkinson disease (PD), progressive supranuclear palsy (PSP), and multiple-system atrophy (MSA) are ...
Parkinson’s disease (PD), caused by a loss of midbrain dopamine neurons, is the second most common n...
The meperidine analogue derivative 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces nigro...
Aim: L-3,4-dihydroxy-6-18F-fluorophenylalanine (FDOPA) PET allows quantification of presynaptic dopa...
Parkinson’s disease (PD) is a highly heterogeneous clinical entity. Patients with young-onset PD (YO...
OBJECTIVES: To examine the distribution of striatal dopaminergic function in humans with parkinsonis...
Transient exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndr...
We have investigated regional changes in dopamine metabolism within the basal ganglia with clinical ...
. .Single photon emission computed tomography SPECT and the dopamine DA transporter tracer, 2 beta-c...
Parkinson\u27s disease (PD) patients have remarkably reduced levels of dopaminergic biomarkers in th...
Neurodegenerative parkinsonisms affect mainly cognitive and motor functions and are syndromes of ove...
Parkinson’s disease (PD) is characterized by the loss of dopamine-producing neurons in the nigrostri...
The MPTP-lesioned monkey is considered as the best animal model for Parkinson's disease (PD). It has...
We investigated the relative differences in dopaminergic function through the whole brain in patient...
Parkinson's disease (PD) is characterized by the loss of dopamine-producing neurons in the nigrostri...
Parkinson disease (PD), progressive supranuclear palsy (PSP), and multiple-system atrophy (MSA) are ...
Parkinson’s disease (PD), caused by a loss of midbrain dopamine neurons, is the second most common n...
The meperidine analogue derivative 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces nigro...
Aim: L-3,4-dihydroxy-6-18F-fluorophenylalanine (FDOPA) PET allows quantification of presynaptic dopa...
Parkinson’s disease (PD) is a highly heterogeneous clinical entity. Patients with young-onset PD (YO...